Nickel deficiency leads to reduced iron content in organs ncI t. re _ _ hem in levels and haematocrit counts. We carried out a clinical trial of oral byposeasitizadea titer.,. wi low doses of nickel on a group of 20 patients affected by systemic allergy to tINsseasidzer ele••at _4 with a chronic relapsing low hemoglobin level and baematocrit COUllt. We oIttailled illterestiJl« reNIiI ell maiataining these values in treated patients.
Nickel is an ubiquitous metal that can be found in different daily-use accessories and utensils. Human exposure to nickel and its derivates derives primarily from food and beverages and is about 3-10J!g/ kg/day (1) (2) . Recent studies show an increasing prevalence of this allergy with an incidence of 10-15% in females and 4-7% in males (3) . Chronic exposition to nickel induces, in some patients, after variable times, a complex syndrome called Systemic Nickel Allergy Syndrome (SNAS), characterized by an association of cutaneous manifestations (chronic eczema, alopecia, urticaria) and systemic symptoms, mainly gastrointestinal (abdominal pain, meteorism, nausea, gastric heartburn, diarrhea and weight gain) (4) (5) . Several studies have demonstrated that oral or intravenous administration of nickel to animals, as a single or repeated doses, could produce changes in the normal tissue absorption, distribution, retention and excretion of some metals, including iron.
We noted that our patients with nickel allergy referred a history of chronic relapsing low anemia, without appare!lt cliftieally-related problems. Therefore, we cM'ried out a clinical trial of oral hyposensitization therapy with low doses of nickel on a group of 20 patients affected by systemic allergy to this sensiUur element and with a referred history of recurrent tow values of hemoglobin and haematocrit count. We screened these hematological parameters before aad after vaccine administration, and we noted a maiBteftllllCe or an improvement of these values in these patients without concomitant iron. administration.
MATERIALS AND METHODS.
We enrolled 20 pMients affected by nickel systemic allergy, confirmed by positive Patch tests with the European standard series for nickel, improvement of cutaneous and systemic symptoms (gastrointestinal, headache, alopecia) after a one-month period of nickelfree diet, and a successive relapsing of these symptoms after the reintroduction of these food.
Patch tests were examined 48-72 hours after their application and were considered positive if an eczematous vesicular reaction occurred at the site of application of contact with the allergen (erythema +/-; erythema, oedema +; erythema, oedema, vesicles, papules ++; intense erythema, oedema, confluent vesicles +++). Inclusion criteria were age > 18 years, a positively mild or severe reaction to Patch tests to nickel, severe cutaneous or gastrointestinal symptoms (abdominal pain, meteorism, nausea, dyspepsia, diarrhoea, anaemia) and a referred history of chronic low values of haemoglobin count and haematocrit value; no celiac disease or gastrointestinal disorders. All the patients gave their fully informed written consent and received granules of a nickel sulphate preparation (l granule containing 0.1 ng three times in the first week; 1 granule containing 0.1 ng every day in the second week; 1 granule containing 1 ng three times in the third week; 1 granule containing 1 ng every day in the fourth week; 1 granule containing lOng three times in the fifth week; 1 granule containing lOng every day in the sixth week; 1 granule containing 100 ng three times in the seventh week; 1 granule containing 100 ng every day in the eighth week; 1 granule containing 500 ng three times in the ninth week; 1 granule containing 500 ng every day in the tenth week; a period of maintenance with 1 or 2 granules containing 500 ng two or three times every week for 1 year). During the first phase the dose was gradually increased and the patients followed a strictly low nickel content diet. Cutaneous symptoms have been associated with a topical therapy with corticosteroid and emollient creams, therefore the patients were recommended to avoid the use of nickel-containing creams, baths or cosmetics. The follow-up consisted of clinical and serological controls after three and six months and after the conclusion of the maintenance phase. The primary end-point was the remission of systemic symptoms and the maintenance of hemoglobin values in the treated patients.
RESULTS
All 20 patients reported an increase of about 0.3-0.4 mgldl of hemoglobin values after the first control carried out three months after the beginning of therapy and an increase of about 0.8-1 mg/dl after one year of treatment. We also observed a median increment value of 5% in the haematocrit value in these patients. None of the patients interrupted the absorption of granules. All 20 patients reported also a significant benefit, of both cutaneous and systemic symptoms, with reduction or absence of itching and dermatitis, reduction of abdominal pain, meteorism and episodes of diarrhea. In two patients we also noted weight loss (about 2 kg) after the first 4 weeks of treatment. No adverse reactions were observed only in eighteen patients, except for mild gastrointestinal manifestations and digestive disorders of low-intensity.
DISCUSSION
A review of the literature revealed that oral or intravenous administration of nickel to animals, as single or repeated dose, could produce changes in the normal tissue absorption, distribution, retention and excretion of some metals, including iron, but the results differed in the reports ofvarious investigators.
First ofall, in 1976 Schnegg et coIl., demonstrated that low nickel concentration could be correlated to a reduced iron content in organs, and to a greatly reduced hemoglobin level and erythrocyte count. In fact, in their study on nickel deficient rats (0.015 ppm dietary nickel) iron absorption was impaired at both 50 and 100 ppm iron in diet; instead, in the rats that received about 20 ppm dietary nickel, the amount of absorbed iron decreased two-thirds and one-third, respectively. Thus, they finally hypothesized that reduced hemoglobin level, erythrocyte count and haematocrit could be caused by impaired absorption of iron, related to a low concentration of nickel (6) .
In 1989 Novell et coll., effectuated a trial to demonstrate the effect of nickel administration on iron deficiency in the gastrointestinal mucosa and in other internal organs; they described that moderate iron deficiency anemia could induce increased lactate-dehydrogenase activity of serum and bone marrow,probably related to the decreased production of energy by oxidative means. They hypothesized also that nickel chloride could inhibit the alteration of hemoglobin synthesis for its capacity to increase iron absorption, with a maintenance ofbone marrow metabolism and an increase ofceruloplasmin activity (7) .
In 1997 Tallkvist et coIl., tried to clarify the absorptive mechanism for iron in the intestinal epithelium; there had been previous reports that demonstrated that various metals, such as nickel, cobalt, cupper, zinc, might be, at least in part, absorbed with the same mechanism. In their trial, they described that renal excretion of nickel was lower in the iron deficient rats than in iron sufficient ones, indicating that iron status could also be related to the uptake of nickel from blood into tissues. Their reports were in line with a previous study (Harris, 1986) , that showed that nickel was able to bind transferrin and that it was taken up in the tissues by the transferring dependent transport mechanism that occurs for iron (8) .
In 2004 Cernpel et coll., performed a trial in which they supplemented the drinking water of rats with nickel, and observed an increasing of iron concentration in various organs (mainly liver, lung and kidney), and in the serum, in line with previous studies (9) . In the same year Latunde-Dada et coll., tried to explain the effects of transition metals, such as cobalt and nickel, on the increase of iron absorption, hemoglobin level and erythrocytes count. They demonstrated -hat cobalt and nickel were inducers of the heme oxygenase, rate limiting enzyme in the heme catabolism, and so they could produce metabolic responses similar to those of hypoxic conditions. They described another mechanism by which these metals could mimic hypoxia: they were able to stabilize or prevent the degradation of hypoxia inducible factor (HIF a), that is a transcriptional activator of EPa (erythropoietin). Increased EPa levels were probably associated with increased erythropoiesis in the spleen and bone marrow (l0).
The results of our study are in line with these laboratory trials; in fact, as in the rats, we tried a stabilization or an improvement of laboratory parameters (hemoglobin and haematocrit value) in our patients after administration of oral low dose nickel-containing granules for one year. These results on patients are very encouraging, but a further period of study is necessary to obtain complete data on the efficacy of this therapy.
